Phase I trial of trispecific T-cell engager clesitamig reports 20.8% response rate in SCLC
Stephen V Liu summarised phase I data on clesitamig, noting cytokine release syndrome was manageable with step-up dosing but that anti-drug antibodies reduced drug exposure.
“immunogenicity an issue with all pts developing ADAs, which reduced exposure.”— Stephen V Liu, MD
A phase I study of clesitamig, a DLL3 x CD3 x 4-1BB trispecific T-cell engager, has been published in a journal tagged as @jitcancer, according to a post on X by thoracic oncologist Stephen V Liu.
Liu said cytokine release syndrome (CRS) occurred in 46.3% of patients. He wrote that with step-up dosing, all cases were grade 2 or lower.
In small cell lung cancer (SCLC), Liu reported a response rate of 20.8% and a duration of response of 4.4 months.
Liu also highlighted immunogenicity as an issue. He wrote that all patients developed anti-drug antibodies (ADAs), which reduced exposure to the drug.
The figures above come from Liu's summary of the study rather than from the full paper.
Original source
“immunogenicity an issue with all pts developing ADAs, which reduced exposure.”
— Stephen V Liu, MD View the post on X